Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.74 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.74 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.74 |
| ▸ | BRAF | P15056 | 19/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL287990 | 0.92 | CYP3A4 (0.63) | CYP3A4CYP2C9CYP2C19BRAF | |
| SCHEMBL30636731 | 0.85 | CYP2C9 (1.00) | CYP3A4CYP2C9CYP2C19BRAF | |
| SCHEMBL285523 | 0.85 | CYP2C9 (1.00) | CYP3A4CYP2C9CYP2C19BRAF | |
| SCHEMBL18043659 | 0.81 | CYP3A4 (0.56) | CYP3A4CYP2C9CYP2C19BRAF | |
| SCHEMBL29561940 | 0.81 | CYP3A4 (0.56) | CYP3A4CYP2C9CYP2C19BRAF | |
| SCHEMBL16253620 | 0.81 | CYP3A4 (0.56) | CYP3A4CYP2C9CYP2C19BRAF | |
| SCHEMBL1437364 | 0.81 | CYP3A4 (0.56) | CYP3A4CYP2C9CYP2C19BRAF | |
| SCHEMBL13961979 | 0.80 | CYP3A4 (0.74) | CYP3A4CYP2C9CYP2C19BRAF | |
| Hydrochloric Acid SCHEMBL27813044 | 0.79 | CYP3A4 (0.72) | CYP3A4CYP2C9CYP2C19BRAF | |
| SCHEMBL913409 | 0.78 | CYP3A4 (0.52) | CYP3A4CYP2C9CYP2C19BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122860-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | PLEXXIKON, INC. | 2012-05-17 | — | — | US | disclosed |
| US-20120122860-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | PLEXXIKON, INC. | 2012-05-17 | — | — | US | disclosed |
| EP-2427433-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | Plexxikon, Inc. (US) | 2012-03-14 | — | — | EP | disclosed |
| WO-2010129570-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | PLEXXIKON, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122860-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | BRAF, RAF1, ARAF | CYP3A4 3611/4885CYP2C9 2176/4885CYP2C19 2730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.